iTeos Therapeutics, Inc.

NasdaqGM:ITOS Stock Report

Market Cap: US$448.7m

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

iTeos Therapeutics Management

Management criteria checks 2/4

iTeos Therapeutics' CEO is Michel Detheux, appointed in Aug 2011, has a tenure of 13.58 years. total yearly compensation is $6.09M, comprised of 10.3% salary and 89.7% bonuses, including company stock and options. directly owns 0.31% of the company’s shares, worth $1.41M. The average tenure of the management team and the board of directors is 5.2 years and 4.3 years respectively.

Key information

Michel Detheux

Chief executive officer

US$6.1m

Total compensation

CEO salary percentage10.33%
CEO tenure14yrs
CEO ownership0.3%
Management average tenure5.2yrs
Board average tenure4.3yrs

Recent management updates

Recent updates

Seeking Alpha • Feb 27

iTeos Therapeutics: Decimated By Collateral Events, Good Chances Of Success Nevertheless

Summary iTeos' lead molecule, Belrestotug, shows promising efficacy in trials despite setbacks in the anti-TIGIT space, with significant partnerships and a strong cash position. The stock has suffered due to failures of similar molecules from competitors, but iTeos' data remains positive, attracting major investments. Financially, iTeos has a solid runway with a market cap of $255mn and cash reserves nearly twice that, ensuring stability. Despite risks, the potential market for anti-TIGIT treatments is vast, and iTeos' strategic partnership with GSK positions it for future success. Read the full article on Seeking Alpha
Seeking Alpha • Dec 18

iTeos Therapeutics: A Perhaps Unjustified Decline To End 2024

Summary iTeos Therapeutics, Inc.'s lead candidate, belrestotug, shows promising response rates in lung cancer but faces challenges with increased toxicity and skepticism due to past failures in similar approaches. The company's financial health is strong, with over half a billion dollars in liquid assets and long-term investments, providing a substantial cushion for ongoing projects. Despite shelving inupadenant, the focus remains on belrestotug, with ongoing trials exploring its potential in various cancer indications. Given the promising data and financial runway, I maintain a Buy sentiment on ITOS stock, despite the inherent risks and market pessimism. Read the full article on Seeking Alpha
Analysis Article • Nov 15

iTeos Therapeutics, Inc. (NASDAQ:ITOS) Third-Quarter Results: Here's What Analysts Are Forecasting For Next Year

iTeos Therapeutics, Inc. ( NASDAQ:ITOS ) shareholders are probably feeling a little disappointed, since its shares fell...
Seeking Alpha • Sep 15

iTeos Therapeutics: ESMO Data Showing Signs Of A Real Win For TIGIT

Summary iTeos Therapeutics' belrestotug shows promising response rates in lung cancer trials, especially when combined with dostarlimab, despite significant safety concerns. Financially, ITOS has over 3 years of cash runway, bolstered by collaboration revenue, supporting its potential to reach critical milestones. The risks include small trial size, potential non-translation of response rates to survival benefits, and high-grade toxicities that could hinder approval. Despite risks, ITOS's market cap of $600 million suggests substantial upside potential if their immunotherapy gains traction, making it a compelling investment thesis. Read the full article on Seeking Alpha
Analysis Article • Aug 11

Is iTeos Therapeutics (NASDAQ:ITOS) In A Good Position To Deliver On Growth Plans?

We can readily understand why investors are attracted to unprofitable companies. For example, although...
Seeking Alpha • Jul 09

iTeos Therapeutics: Rippling Waves Of TIGIT Pessimism

Summary iTeos Therapeutics is developing an anti-TIGIT molecule for various cancers, partnering with GSK and advancing to late-stage clinical studies. Their main clinical focus is belrestotug, aiming to differentiate from other anti-TIGIT approaches, with positive interim data readouts. Financially, ITOS has a strong balance sheet with significant cash reserves, but faces risks from unproven TIGIT targets and market valuation fluctuations. Read the full article on Seeking Alpha
Analysis Article • Jan 25

iTeos Therapeutics, Inc. (NASDAQ:ITOS) Looks Inexpensive But Perhaps Not Attractive Enough

With a price-to-sales (or "P/S") ratio of 5.3x iTeos Therapeutics, Inc. ( NASDAQ:ITOS ) may be sending very bullish...
Seeking Alpha • Jan 10

iTeos: Readouts From TIGIT And Adenosine Pathway Inhibitors Makes This A Must Watch

Summary Data readout from phase 2 GALAXIES Lung-201 study, using belrestotug in combination with dostarlimab to treat patients with 1st-line advanced/metastatic NSCLC, expected 2024. The global non-small cell lung cancer market is expected to reach $36.9 billion by 2031. Data readout from phase 2 TIGIT-006 study, using belrestotug in combination with dostarlimab for the treatment of patients with head and neck squamous cell carcinoma, expected 2024. The global head and neck cancer drugs market size is expected to surpass $3.9 billion by 2030. Read the full article on Seeking Alpha
Analysis Article • May 13

Industry Analysts Just Upgraded Their iTeos Therapeutics, Inc. (NASDAQ:ITOS) Revenue Forecasts By 16%

Celebrations may be in order for iTeos Therapeutics, Inc. ( NASDAQ:ITOS ) shareholders, with the analysts delivering a...
Analysis Article • Mar 21

Investors Give iTeos Therapeutics, Inc. (NASDAQ:ITOS) Shares A 25% Hiding

iTeos Therapeutics, Inc. ( NASDAQ:ITOS ) shareholders that were waiting for something to happen have been dealt a blow...
Analysis Article • Aug 12

The Consensus EPS Estimates For iTeos Therapeutics, Inc. (NASDAQ:ITOS) Just Fell Dramatically

The analysts covering iTeos Therapeutics, Inc. ( NASDAQ:ITOS ) delivered a dose of negativity to shareholders today, by...
Seeking Alpha • Aug 10

iTeos Therapeutics GAAP EPS of $0.16 misses by $1.04

iTeos Therapeutics press release (NASDAQ:ITOS): Q2 GAAP EPS of $0.16 misses by $1.04. The company’s cash and cash equivalent position was $791.9 million as of June 30, 2022, as compared to $302.9 million as of June 30, 2021. Cash balance is expected to provide the company runway into 2026..
Seeking Alpha • Jul 27

iTeos Therapeutics: Too Many Unknowns

Today, we put clinical stage oncology concern iTeos Therapeutics, Inc. in the spotlight for the first time. The company has two main oncology assets in development and a big partnership with GlaxoSmithKline. An investment analysis follows in the paragraphs below. Dandelions spring up where cities have been destroyed.”― Marty Rubin Today, we put iTeos Therapeutics, Inc. (ITOS) in the spotlight for the first time. This small cap oncology concern has a major partnership with a large drug maker and has two primary drug candidates under development. An analysis follows below. Seeking Alpha Company Overview iTeos Therapeutics, Inc. is a clinical-stage biopharmaceutical company headquartered just outside of Boston in Watertown, MA. The company also has a research center in Gosselies, Belgium. The firm is focused on the discovery and development of immuno-oncology therapeutics for patients. The stock currently trades around $25.00 a share and came public in the summer of 2020. It was founded in 2013. Its shares have an approximate market value of $900 million. iTeos Therapeutics has two clinical-stage product candidates, EOS-448 and Inupadenant, in development. Both target a key mechanism that inhibits an effective antitumor immune response. March Company Presentation EOS-448: This is an anti-TIGIT human immunoglobulin G1, or IgG1, antibody that the company is developing to inhibit the immunosuppressive activity of TIGIT. TIGIT is a cell surface receptor expressed on multiple immune cells, including CD8+ T cells, natural killer, or NK, cells and T regulatory cells. EOS-448 binds with high affinity to TIGIT, thereby breaking the immunosuppressive interaction between TIGIT and its ligands. It can also activate FcγR on macrophages, dendritic cells and NK cells in the tumor microenvironment. March Company Presentation According to the company website: This activation of these cells augments the anti-tumor immune response but also triggers Antibody Dependent Cellular Cytotoxicity or ADCC response to those cells which expressed the highest levels of TIGIT, the Tregs." EOS-448 is being developed jointly with GlaxoSmithKline (GSK) under a collaboration arrangement reached last Spring (see below section for details). This is the largest of several developmental partnerships the company has sealed. iTeos has initiated several 1b/2a studies around EOS-448 involving four combo therapies and targeting three indications. March Company Presentation It should be noted that Glaxo and iTeos are working together to evaluate how best to proceed with additional clinical development of EOS-448 in light of the recent release regarding the Roche (RHHBY) SKYSCRAPER-01 study which came out in Mid-May and did not meet its primary endpoint. This trial involved another anti-TIGIT program. Enrollment is also underway in a clinical trial evaluating EOS-448 as both a monotherapy and in combination with Bristol Myers Squibb’s (BMY) iberdomide in patients with multiple myeloma, one of several efforts outside the joint development program with Glaxo. The second compound in development is Inupadenant. This compound is designed to inhibit the ATP-adenosine pathway by specifically targeting A2AR. This is the primary adenosine receptor on immune cells with a high affinity for adenosine. This pathway is recognized as a key pathway that modulates immune responses in pathological conditions. March Company Presentation This candidate is in a much earlier stage of development. The company is in the process of initiating a randomized Phase 2 trial mid-year in metastatic non-small cell lung cancer (mNSCLC) to evaluate the combination of inupadenant with chemotherapy compared to standard of care. iTeos is also enrolling patients in a Phase 2a trial evaluating inupadenant in combination with pembrolizumab in PD-1 resistant melanoma. Analyst Commentary & Balance Sheet Four analyst firms including JPMorgan and Wedbush have reissued Buy ratings on the stock since Mid-May. Price targets proffered range from $34 to $52 a share.
Analysis Article • May 11

News Flash: Analysts Just Made A Captivating Upgrade To Their iTeos Therapeutics, Inc. (NASDAQ:ITOS) Forecasts

Celebrations may be in order for iTeos Therapeutics, Inc. ( NASDAQ:ITOS ) shareholders, with the analysts delivering a...
Analysis Article • Nov 25

Rainbows and Unicorns: iTeos Therapeutics, Inc. (NASDAQ:ITOS) Analysts Just Became A Lot More Optimistic

Celebrations may be in order for iTeos Therapeutics, Inc. ( NASDAQ:ITOS ) shareholders, with the analysts delivering a...

CEO Compensation Analysis

How has Michel Detheux's remuneration changed compared to iTeos Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2025n/an/a

-US$202m

Mar 31 2025n/an/a

-US$131m

Dec 31 2024US$6mUS$629k

-US$134m

Sep 30 2024n/an/a

-US$121m

Jun 30 2024n/an/a

-US$108m

Mar 31 2024n/an/a

-US$135m

Dec 31 2023US$6mUS$579k

-US$113m

Sep 30 2023n/an/a

-US$62m

Jun 30 2023n/an/a

-US$28m

Mar 31 2023n/an/a

US$12m

Dec 31 2022US$11mUS$556k

US$97m

Sep 30 2022n/an/a

US$261m

Jun 30 2022n/an/a

US$330m

Mar 31 2022n/an/a

US$298m

Dec 31 2021US$6mUS$525k

US$215m

Sep 30 2021n/an/a

US$15m

Jun 30 2021n/an/a

-US$67m

Mar 31 2021n/an/a

-US$50m

Dec 31 2020US$17mUS$463k

-US$43m

Sep 30 2020n/an/a

-US$35m

Jun 30 2020n/an/a

-US$31m

Mar 31 2020n/an/a

-US$28m

Dec 31 2019US$2mUS$460k

-US$27m

Compensation vs Market: Michel's total compensation ($USD6.09M) is above average for companies of similar size in the US market ($USD2.44M).

Compensation vs Earnings: Michel's compensation has increased whilst the company is unprofitable.

CEO

Michel Detheux (59 yo)

14yrs
Tenure
US$6,085,657
Compensation

Dr. Michel Detheux, Ph D, has been the Director of Vor Biopharma Inc. since July 16, 2025. He is Chairman of the Board at InnoSkel.He serves as an Independent Chairman at Ona Therapeutics, S.L. since Dece...

Leadership Team

NamePositionTenureCompensationOwnership
Michel Detheux
President14yrsUS$6.09m0.31%
$ 1.4m
Matthew Call
Chief Operating Officer6yrsUS$2.62m0.21%
$ 953.1k
David Feltquate
Chief Medical Officer1yrUS$5.35m0%
$ 0
Matthew Gall
Chief Financial Officer5.2yrsUS$2.72m0.055%
$ 247.9k
Yvonne McGrath
Chief Scientific Officer3.6yrsno datano data
Adi Osovsky
Executive Vice President of Legal2.6yrsno datano data
Philippe Brantegem
Chief People Officer5.6yrsno datano data
5.2yrs
Average Tenure
51.5yo
Average Age

Experienced Management: ITOS's management team is seasoned and experienced (5.2 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Michel Detheux
President13.6yrsUS$6.09m0.31%
$ 1.4m
Ann Rhoads
Independent Director5.2yrsUS$345.57k0%
$ 0
David Hallal
Independent Chairman of the Board7.2yrsUS$442.82k0%
$ 0
Matthew Vander Heiden
Member of Scientific Advisory Boardno datano datano data
Jill DeSimone
Independent Director1.4yrsUS$686.27k0%
$ 0
Tony W. Ho
Independent Director4.3yrsUS$332.76k0%
$ 0
Robert Iannone
Independent Director4.3yrsUS$341.26k0%
$ 0
David Lee
Independent Director1.7yrsUS$320.07k0%
$ 0
Gordon Freeman
Chairman of Scientific Advisory Boardno datano datano data
Benoit Van den Eynde
Member of Scientific Advisory Boardno datano datano data
Florent Ginhoux
Member of Scientific Advisory Boardno datano datano data
Roberta Zappasodi
Member of Scientific Advisory Boardno datano datano data
4.3yrs
Average Tenure
59yo
Average Age

Experienced Board: ITOS's board of directors are considered experienced (4.3 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/08/30 18:03
End of Day Share Price 2025/08/28 00:00
Earnings2025/06/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

iTeos Therapeutics, Inc. is covered by 3 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Michael UlzBaird
Derek ArchilaWells Fargo Securities, LLC
Eva Fortea-VerdejoWells Fargo Securities, LLC